Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
24.77
+0.67 (2.78%)
At close: Aug 11, 2026, 4:00 PM EDT
25.23
+0.46 (1.86%)
After-hours: Aug 11, 2026, 7:34 PM EDT
Aktis Oncology Revenue
Aktis Oncology had revenue of $3.23M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $8.28M, up 1,394.04% year-over-year. In the year 2025, Aktis Oncology had annual revenue of $6.50M with 336.92% growth.
Revenue (ttm)
$8.28M
Revenue Growth
+1,394.04%
P/S Ratio
165.42
Revenue / Employee
$104,772
Employees
79
Market Cap
1.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.50M | 5.01M | 336.92% |
| Dec 31, 2024 | 1.49M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
AKTS News
- 4 weeks ago - Aktis Oncology price target raised to $33 from $30 at JPMorgan - TheFly
- 2 months ago - Aktis Oncology initiated with a Strong Buy at Raymond James - TheFly
- 2 months ago - Aktis Oncology Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Aktis Oncology Slides: FY 2026 - Filings
- 2 months ago - Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright - TheFly
- 2 months ago - Aktis Oncology to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Aktis Oncology Transcript: Status update - Transcripts
- 2 months ago - Aktis Oncology Slides: Status update - Filings